Skip to content

A Single Arm Feasibility Study of GlycoLeap, an On-line Lifestyle Modification and Self-management Program for People With Type 2 Diabetes

A Single Arm Feasibility Study of GlycoLeap, an On-line Lifestyle Modification and Self-management Program for People With Type 2 Diabetes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03091517
Enrollment
100
Registered
2017-03-27
Start date
2017-06-22
Completion date
2018-05-28
Last updated
2018-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Keywords

Online lifestyle modification, Self-management, HbA1c

Brief summary

This single arm pilot study will explore the feasibility of GlycoLeap, a proprietary online lifestyle modification and self-management education program developed in Singapore for people with type 2 diabetes, as an add-on to primary care delivered through one of the SingHealth Polyclinics.

Detailed description

Lifestyle modification - focusing on a healthy diet, regular exercise and behaviour change - are the mainstay of first-line therapies in managing diabetes. There is strong evidence that lifestyle interventions can result in modest weight loss and improvements in clinical metrics such as glycated haemoglobin (HbA1c), blood pressure and cholesterol. For people with type 2 diabetes, lifestyle modification and self-management education can lead to improved clinical outcomes and reduced risks of complications. Operationally, such interventions are often difficult to administer in the primary care and community setting because of lack of provider time/resources/training and difficulty in engaging patients. Fortunately, there is a growing body of evidence which shows that online programs and smartphone-based interventions can lead to improved clinical outcomes like weight loss and HbA1c reduction. Moreover, these interventions can be disseminated to a larger group of people and at a low cost. However, results from community based studies often fail to live up to what is achieved in clinical trials due to lack of clinician oversight and support. Without this support, patients often fail to engage in the intervention to the levels required for health benefits to materialize. This feasibility study will explore the use of GlycoLeap, a proprietary online lifestyle modification and self-management education program developed in Singapore for people with type 2 diabetes, as an add-on to primary care delivered through one of the SingHealth Polyclinics. The goal of the study is to test whether patients with diabetes who receive care at the clinic are amenable to such an intervention, to quantify program fidelity for those who do enroll in the study, and to explore the extent to which the intervention can be used in conjunction with primary care in efforts to improve health outcomes.

Interventions

BEHAVIORALGlycoLeap

GlycoLeap is a 24-week programme includes the following features: Interactive Education Lessons: Beginning week 1, the participant will be presented with a diabetes self-management education curriculum. These lessons are divided into 6 phases, and each lesson is fully accessible online from a computer or mobile phone, and takes approximately 10 - 15 minutes to complete. The Glyco Mobile Application: During the 24 week intervention period, the participant will use the Glyco mobile application that allows them to track their weight (measured on the wireless weighing scale), self-tested glucose readings (measured using the glucometer kit), and log their foods and meals by taking photos using their phone. A health coach will review the participant's data regularly, provide personalised feedback.

Sponsors

SingHealth Polyclinics
CollaboratorOTHER
Duke-NUS Graduate Medical School
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Age 21 - 70 years 2. Medical diagnosis of Type 2 diabetes in electronic health records or based on World Health Organisation diagnostic criteria 3. Last HbA1c result within 2 months of ≥ 7.5% 4. BMI \> 23 kg/m2 (if Asian) or BMI \> 25 kg/m2 (if non-Asian) 5. Not on insulin 6. Owns a smartphone (iPhone or Android phone) and able to use it

Exclusion criteria

1. Last HbA1c blood test older than 2 months 2. Cancer requiring treatment in past 5 years 3. Cardiovascular disease (heart attack or cardiac procedure within past 3 months) 4. Stroke or history/treatment for transient ischemic attacks in past 3 months 5. Chronic renal failure or dialysis 6. Amputation of lower limbs 7. Current use of medication for weight loss 8. Chronic treatment with systemic corticosteroids 9. History of bariatric surgery or extensive bowel resection 10. Unable to understand English

Design outcomes

Primary

MeasureTime frameDescription
Change in HbA1c levels (Effectiveness)Baseline, Month 6HbA1c or glycated haemoglobin is a measure of blood glucose levels. We will assess change in HbA1c levels.

Secondary

MeasureTime frameDescription
Proportion of individuals who are willing to participate (Reach)BaselinePercentage of participants offered the GlycoLeap programme who agree to enrol
Extent of engagement in completing online health lessons (Implementation)Throughout 6 month intervention durationNumber of online GlycoLeap health lessons completed
Extent of engagement in submitting blood glucose logs (Implementation)Throughout 6 month intervention durationNumber of blood glucose measurements logged per week in GlycoLeap's smartphone app
Extent of engagement in submitting weight logs (Implementation)Throughout 6 month intervention durationNumber of weight measurements logged per week in GlycoLeap's smartphone app
Change in weight (Effectiveness)Baseline, Month 6We will assess change in weight
Extent of engagement with health coach (Implementation)Throughout 6 month intervention durationNumber of messages sent to health coaches per week through GlycoLeap's smartphone app
Change in HbA1c (primary outcome) as a function of program engagement (Effectiveness)Baseline, Month 6, Throughout 6 month intervention durationWe will test whether those with greater engagement with the GlycoLeap program show greater improvements in HbA1c (primary outcome).
Change in weight loss (secondary outcome) as a function of program engagement (Effectiveness)Baseline, Month 6, Throughout 6 month intervention durationWe will test whether those with greater engagement with the GlycoLeap program show greater improvements in weight loss (secondary outcome).
Degree of user satisfaction with the GlycoLeap program (Maintenance)Month 6We will conduct a preliminary assessment of maintenance at the individual level via a user satisfaction survey at the month 6 follow-up. Participants will rate the smartphone app on a scale of 1 (Poor) to 5 (Excellent) and whether they would recommend the app to others for managing their diabetes on a scale of 1 (Would not recommend) to 5 (Would highly recommend).
Extent of engagement in submitting meal logs (Implementation)Throughout 6 month intervention durationNumber of meals logged per week in GlycoLeap's smartphone app

Countries

Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026